The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help
Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocationa...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 22; no. 1; pp. 705 - 9 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
15.10.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population.
The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD.
The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery.
ClinicalTrials.gov NCT04289415 . Registered on February 28, 2020. |
|---|---|
| AbstractList | Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population.
The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD.
The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery.
ClinicalTrials.gov NCT04289415 . Registered on February 28, 2020. Background Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population. Methods/design The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD. Discussion The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery. Trial registration ClinicalTrials.gov NCT04289415. Registered on February 28, 2020 Keywords: Substance use disorders, SUD, Individual Placement and Support, IPS, Employment support, Rehabilitation, Drugs, Dependence, Addiction, Treatment Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population. The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD. The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery. BackgroundEmployment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population.Methods/designThe IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD.DiscussionThe IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery.Trial registrationClinicalTrials.gov NCT04289415. Registered on February 28, 2020 Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population.BACKGROUNDEmployment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population.The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD.METHODS/DESIGNThe IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD.The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery.DISCUSSIONThe IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery.ClinicalTrials.gov NCT04289415 . Registered on February 28, 2020.TRIAL REGISTRATIONClinicalTrials.gov NCT04289415 . Registered on February 28, 2020. Abstract Background Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population. Methods/design The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD. Discussion The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery. Trial registration ClinicalTrials.gov NCT04289415 . Registered on February 28, 2020 Abstract Background Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high for people with substance use disorders (SUD) who undergo treatment, with Norwegian estimates ranging from 81 to 91%. Evidence-based vocational models are lacking for patients in SUD treatment but exist for patients with psychosis in terms of Individual Placement and Support (IPS). The aim of the IPS for substance use disorders (IPS-SUD) trial is to investigate the effect of IPS in a SUD population. Methods/design The IPS-SUD trial is a randomized controlled trial (RCT) comparing IPS to an enhanced control intervention. The study is a seven-site, two-arm, pragmatic, parallel-group, superiority RCT. Participants are randomly assigned (1:1) to receive either IPS plus treatment as usual (TAU) or to receive a self-help guide book and 12-h workshop plus 1-h individual vocational guidance plus TAU. Aiming to recruit 200 participants, we will be able to detect a 20% difference in the main outcome of employment with 90% power. We will make assessments at inclusion and at 6- and 12-month follow-ups and obtain outcome data on employment from national mandatory registries. The primary outcome will be at least 1 day of competitive employment during the 18-month follow-up period. Secondary employment outcomes will capture the pattern and extent of employment in terms of total time worked (days/hours), time to first employment, number of different jobs, duration of the longest employment, and sustained employment. Secondary non-employment outcomes will be substance use, mental distress, and quality of life measured by validated instruments at 6, 12, and 18 months follow-up assessments. To be eligible, participants must be between 18 and 65 years, currently unemployed and in treatment for SUD. Discussion The IPS-SUD trial will provide evidence for the use of IPS in a SUD population. Findings from the study will have implications for service delivery. Trial registration ClinicalTrials.gov NCT04289415 . Registered on February 28, 2020 |
| ArticleNumber | 705 |
| Audience | Academic |
| Author | Arnevik, Espen Ajo Aas, Erlend Marius Drake, Robert E Bond, Gary R Reme, Silje Endresen Lystad, June Ullevoldsæter Rognli, Eline Borger Anders, Paul Marsden, John |
| Author_xml | – sequence: 1 givenname: Eline Borger orcidid: 0000-0002-7248-3019 surname: Rognli fullname: Rognli, Eline Borger email: elboka@ous-hf.no organization: Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway. elboka@ous-hf.no – sequence: 2 givenname: Erlend Marius surname: Aas fullname: Aas, Erlend Marius organization: Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway – sequence: 3 givenname: Robert E surname: Drake fullname: Drake, Robert E organization: IPS Employment Center, Laconia, New Hampshire, USA – sequence: 4 givenname: John surname: Marsden fullname: Marsden, John organization: Addictions Department, Institute of Psychiatry, King's College London, London, UK – sequence: 5 givenname: Paul surname: Anders fullname: Anders, Paul organization: Public Health England, London, UK – sequence: 6 givenname: Gary R surname: Bond fullname: Bond, Gary R organization: IPS Employment Center, Laconia, New Hampshire, USA – sequence: 7 givenname: June Ullevoldsæter surname: Lystad fullname: Lystad, June Ullevoldsæter organization: Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway – sequence: 8 givenname: Silje Endresen surname: Reme fullname: Reme, Silje Endresen organization: Faculty of Social Sciences, University of Oslo, Oslo, Norway – sequence: 9 givenname: Espen Ajo surname: Arnevik fullname: Arnevik, Espen Ajo organization: Division of Mental Health and Addiction, Oslo University Hospital, P.O. Box 4956 Nydalen, 0424, Oslo, Norway |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34654464$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl1vFCEUhiemxn7oH_DCkHhTL6bC8DEzXpg0jR-bNLHJ1mvCwmGXZhZGYNZ0f5s_TrZba2sMFxA473Pg5T2uDnzwUFWvCT4jpBPvE6FY0Bo3pMZctLTePquOSMt4LRrCDx6tD6vjlG4wZrSn7EV1SJngjAl2VP26XgECa0FnBBs1TCq74FGwaOaN2zgzqQFdDUrDGnxGyhs0n8YxxIxOZ1fzd8iGiMYiKqcJ_XR5hdK0SFl5DWhKgIxLIRqI6QNKeTK3aIwhBx2GO6VCsSDD2m3BIB18jmEYyjJHV_rubnE1R5uinhICv9pRDUow2HoFw_iyem7VkODV_XxSff_86fria3357cvs4vyy1lzQXGvFAYwA0tIWOmo6ZTFTilADivGFbRvDabvoNLVcG963RBjRYq76YrPVLT2pZnuuCepGjtGtVbyVQTl5txHiUqqYnR5A9lpj1SjB8MIyi0Xfi4YvAAPpqe6MLqyPe9Y4LdZgdPEtquEJ9OmJdyu5DBvZcdI1pCuA03tADD8mSFmuXdIwDMpDmJJseNd0hDEiSunbf0pvwhR9sUo2LcWU9lzwv1VLVR7gvA2lr95B5bnoCoaIZufB2X-qyjCwduXnwLqy_0TQ7AU6hpQi2Ic3Eix3-ZX7_MqSX3mXX7ktojeP3XmQ_Aks_Q2RG_CN |
| CitedBy_id | crossref_primary_10_1186_s13063_024_08007_x crossref_primary_10_1080_14659891_2023_2281966 crossref_primary_10_1177_14550725221122196 crossref_primary_10_1080_15504263_2024_2341092 crossref_primary_10_1002_pcn5_122 crossref_primary_10_52734_2h82w7yP |
| Cites_doi | 10.1192/bjp.179.6.540 10.1192/bjp.180.5.461 10.1186/s12888-016-1183-0 10.1016/j.drugalcdep.2018.03.052 10.1111/acps.13129 10.1016/S0140-6736(12)62160-6 10.1007/s10488-017-0793-2 10.1176/appi.ps.201100270 10.1159/000259089 10.1186/s13063-020-4099-4 10.2174/1874473711104010004 10.1080/14659890410001697415 10.1186/s12955-018-1029-1 10.5271/sjweh.3753 10.1186/1745-6215-11-32 10.1093/acprof:oso/9780199734016.001.0001 10.1176/appi.ps.201800464 10.1002/pmh.1382 10.1186/s12874-017-0442-1 10.1192/bjp.bp.114.152082 10.1080/10826084.2017.1413114 10.1016/0168-8510(96)00822-6 10.1016/j.jsat.2018.01.015 10.1787/9789264178984-en 10.5271/sjweh.3837 10.1080/15504263.2011.568360 10.1176/appi.ps.201500058 10.1192/bjp.bp.115.165092 10.1176/appi.ps.201100476 10.1111/j.1600-0447.1983.tb09716.x |
| ContentType | Journal Article |
| Copyright | 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-021-05673-z |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_9cc0a2a640bf4f0699625be0e193c8dc A681631627 10_1186_s13063_021_05673_z 34654464 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | Norway United States--US |
| GeographicLocations_xml | – name: Norway – name: United States--US |
| GroupedDBID | --- -5E -5G -A0 -BR 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ NPM O5R O5S PGMZT PIMPY PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX CITATION ABVAZ AFGXO AFNRJ 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO FRP K9. PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c563t-ca5eed6e1737e83d8af04aa13dea45bf72d537b8c3f5cd59716d6705a9118fc73 |
| IEDL.DBID | RPM |
| ISSN | 1745-6215 |
| IngestDate | Fri Oct 04 13:06:47 EDT 2024 Tue Sep 17 21:27:26 EDT 2024 Sat Aug 17 16:31:15 EDT 2024 Thu Oct 10 19:51:19 EDT 2024 Thu Feb 22 23:36:20 EST 2024 Fri Feb 02 04:30:25 EST 2024 Thu Sep 12 16:46:15 EDT 2024 Fri Oct 18 09:17:21 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Drugs Substance use disorders SUD Treatment Addiction Dependence Individual Placement and Support Rehabilitation Employment support IPS |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c563t-ca5eed6e1737e83d8af04aa13dea45bf72d537b8c3f5cd59716d6705a9118fc73 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0002-7248-3019 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518218/ |
| PMID | 34654464 |
| PQID | 2730339565 |
| PQPubID | 44365 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9cc0a2a640bf4f0699625be0e193c8dc pubmedcentral_primary_oai_pubmedcentral_nih_gov_8518218 proquest_miscellaneous_2582814416 proquest_journals_2730339565 gale_infotracmisc_A681631627 gale_infotracacademiconefile_A681631627 crossref_primary_10_1186_s13063_021_05673_z pubmed_primary_34654464 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-15 |
| PublicationDateYYYYMMDD | 2021-10-15 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | GR Bond (5673_CR36) 2012; 63 KT Mueser (5673_CR12) 2011; 7 G Pedersen (5673_CR33) 2017; 11 JC Mundt (5673_CR32) 2002; 180 Velferdsetaten (5673_CR19) 2019 D Henkel (5673_CR3) 2011; 4 A-W Chan (5673_CR24) 2013; 381 JR Carpenter (5673_CR37) 2007 G Lauritzen (5673_CR17) 2012 E Falkum (5673_CR20) 2017; 17 G Lauritzen (5673_CR31) 2004; 9 B Eastwood (5673_CR2) 2018; 188 AS Zigmond (5673_CR28) 1983; 67 M Modini (5673_CR8) 2016; 209 GR Bond (5673_CR27) 2012; 63 JC Jakobsen (5673_CR38) 2017; 17 5673_CR14 5673_CR15 5673_CR18 RT Sherba (5673_CR5) 2018; 87 KF Abel (5673_CR16) 2018; 53 A Mykletun (5673_CR29) 2001; 179 5673_CR6 V Sveinsdottir (5673_CR22) 2019; 46 5673_CR1 J Marsden (5673_CR13) 2020; 21 T Burns (5673_CR26) 2015; 207 5673_CR4 R Brooks (5673_CR34) 1996; 37 5673_CR9 RE Drake (5673_CR7) 2012 5673_CR21 5673_CR25 KF Schulz (5673_CR23) 2010; 11 K Stavem (5673_CR35) 2018; 16 A Kokkevi (5673_CR30) 1995; 1 CE Lones (5673_CR10) 2017; 44 JP LePage (5673_CR11) 2016; 67 |
| References_xml | – volume-title: Missing data in randomised controlled trials: a practical guide year: 2007 ident: 5673_CR37 contributor: fullname: JR Carpenter – volume: 179 start-page: 540 issue: 6 year: 2001 ident: 5673_CR29 publication-title: Br J Psychiatry. doi: 10.1192/bjp.179.6.540 contributor: fullname: A Mykletun – volume: 180 start-page: 461 issue: 5 year: 2002 ident: 5673_CR32 publication-title: Br J Psychiatry. doi: 10.1192/bjp.180.5.461 contributor: fullname: JC Mundt – volume: 17 start-page: 24 issue: 1 year: 2017 ident: 5673_CR20 publication-title: BMC Psychiatry. doi: 10.1186/s12888-016-1183-0 contributor: fullname: E Falkum – ident: 5673_CR25 – volume: 188 start-page: 200 year: 2018 ident: 5673_CR2 publication-title: Drug Alcohol Depend. doi: 10.1016/j.drugalcdep.2018.03.052 contributor: fullname: B Eastwood – ident: 5673_CR6 doi: 10.1111/acps.13129 – volume: 381 start-page: 91 issue: 9861 year: 2013 ident: 5673_CR24 publication-title: Lancet. doi: 10.1016/S0140-6736(12)62160-6 contributor: fullname: A-W Chan – volume: 44 start-page: 359 issue: 3 year: 2017 ident: 5673_CR10 publication-title: Adm Policy Mental Health Ment Health Serv Res. doi: 10.1007/s10488-017-0793-2 contributor: fullname: CE Lones – volume: 63 start-page: 751 issue: 8 year: 2012 ident: 5673_CR36 publication-title: Psychiatr Serv. doi: 10.1176/appi.ps.201100270 contributor: fullname: GR Bond – volume: 1 start-page: 208 issue: 4 year: 1995 ident: 5673_CR30 publication-title: Eur Addict Res. doi: 10.1159/000259089 contributor: fullname: A Kokkevi – volume: 21 start-page: 1 issue: 1 year: 2020 ident: 5673_CR13 publication-title: Trials. doi: 10.1186/s13063-020-4099-4 contributor: fullname: J Marsden – volume: 4 start-page: 4 issue: 1 year: 2011 ident: 5673_CR3 publication-title: Curr Drug Abuse Rev. doi: 10.2174/1874473711104010004 contributor: fullname: D Henkel – volume: 9 start-page: 141 issue: 3-4 year: 2004 ident: 5673_CR31 publication-title: J Subst Use. doi: 10.1080/14659890410001697415 contributor: fullname: G Lauritzen – volume: 16 start-page: 204 issue: 1 year: 2018 ident: 5673_CR35 publication-title: Health Qual Life Outcomes. doi: 10.1186/s12955-018-1029-1 contributor: fullname: K Stavem – ident: 5673_CR21 doi: 10.5271/sjweh.3753 – volume: 11 start-page: 1 issue: 1 year: 2010 ident: 5673_CR23 publication-title: Trials. doi: 10.1186/1745-6215-11-32 contributor: fullname: KF Schulz – volume-title: Individual placement and support: an evidence-based approach to supported employment year: 2012 ident: 5673_CR7 doi: 10.1093/acprof:oso/9780199734016.001.0001 contributor: fullname: RE Drake – ident: 5673_CR1 – ident: 5673_CR9 doi: 10.1176/appi.ps.201800464 – volume: 11 start-page: 215 issue: 4 year: 2017 ident: 5673_CR33 publication-title: Pers Soc Psychol Bull. doi: 10.1002/pmh.1382 contributor: fullname: G Pedersen – ident: 5673_CR18 – volume: 17 start-page: 1 issue: 1 year: 2017 ident: 5673_CR38 publication-title: BMC Med Res Methodol. doi: 10.1186/s12874-017-0442-1 contributor: fullname: JC Jakobsen – volume: 207 start-page: 351 issue: 4 year: 2015 ident: 5673_CR26 publication-title: Br J Psychiatry. doi: 10.1192/bjp.bp.114.152082 contributor: fullname: T Burns – volume: 53 start-page: 1454 issue: 9 year: 2018 ident: 5673_CR16 publication-title: Subst Use Misuse. doi: 10.1080/10826084.2017.1413114 contributor: fullname: KF Abel – volume: 37 start-page: 53 issue: 1 year: 1996 ident: 5673_CR34 publication-title: Health Policy. doi: 10.1016/0168-8510(96)00822-6 contributor: fullname: R Brooks – volume: 87 start-page: 70 year: 2018 ident: 5673_CR5 publication-title: J Subst Abuse Treat. doi: 10.1016/j.jsat.2018.01.015 contributor: fullname: RT Sherba – ident: 5673_CR14 doi: 10.1787/9789264178984-en – volume: 46 start-page: 50 issue: 1 year: 2019 ident: 5673_CR22 publication-title: Scand J Work Environ Health. doi: 10.5271/sjweh.3837 contributor: fullname: V Sveinsdottir – volume-title: Helhetlig russtatistikk Oslo kommune 2018/2019 year: 2019 ident: 5673_CR19 contributor: fullname: Velferdsetaten – volume: 7 start-page: 90 issue: 1-2 year: 2011 ident: 5673_CR12 publication-title: J Dual Diagn. doi: 10.1080/15504263.2011.568360 contributor: fullname: KT Mueser – ident: 5673_CR4 – volume: 67 start-page: 735 issue: 7 year: 2016 ident: 5673_CR11 publication-title: Psychiatr Serv. doi: 10.1176/appi.ps.201500058 contributor: fullname: JP LePage – ident: 5673_CR15 – volume-title: Gjennom 10 år. En oppfølgingsstudie av narkotikabrukere i behandling year: 2012 ident: 5673_CR17 contributor: fullname: G Lauritzen – volume: 209 start-page: 14 issue: 1 year: 2016 ident: 5673_CR8 publication-title: Br J Psychiatry. doi: 10.1192/bjp.bp.115.165092 contributor: fullname: M Modini – volume: 63 start-page: 758 issue: 8 year: 2012 ident: 5673_CR27 publication-title: Psychiatr Serv. doi: 10.1176/appi.ps.201100476 contributor: fullname: GR Bond – volume: 67 start-page: 361 issue: 6 year: 1983 ident: 5673_CR28 publication-title: Acta Psychiatr Scand. doi: 10.1111/j.1600-0447.1983.tb09716.x contributor: fullname: AS Zigmond |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.3632405 |
| Snippet | Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates are high... Abstract Background Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion.... Background Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates... BackgroundEmployment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion. Unemployment rates... Abstract Background Employment is associated with better outcomes of substance use treatment and protects against relapse after treatment completion.... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 705 |
| SubjectTerms | Care and treatment Clinical trials Drug use Economic conditions Employment Employment support Employment, Supported Guidebooks Humans Individual Placement and Support IPS Mental Disorders Patients Psychotic Disorders Randomized Controlled Trials as Topic Rehabilitation Rehabilitation, Vocational Self help Social aspects Study Protocol Substance abuse treatment Substance abusers Substance use disorder Substance use disorders Substance-Related Disorders - diagnosis Substance-Related Disorders - therapy SUD Unemployment Workshops Young adults |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G31lBEEFSnXNp_r2yked8LJwnlwbyFNUvZgrz3s7sv-bf5xzqTddYsPvvhWmhTSzGTmN8nML4y99ZrqNYPOYy1FLkpac7PCY9TqZo2W3khPhcLn39Xppfh2Ja_2rvqinLCBHniYuKOZ94WrnBJF3YimUIjPK1nHIiLy8Cb4ZH1LuQ2mBhuMXpaLbYmMUUc9Wup0Xomhs1Sa55uJG0ps_X_b5D2nNE2Y3PNAJw_Y_RE6wvEw5IfsTmwfsbvn4-H4Y_YLRQ5Dfgb8IfGGroGzXdUVzGnbnHYEwbUB6E5PxN_w_mx-8QEQv8LIs9oDbdBCj2ZlRXoB6z5CGJk6-0-QWGmBSB461KT0pQN0e6G7ud7EAGMG_BIf070gaRTzC6AkkHUPsV2kzAPo47LJF3F5-4Rdnnz98eU0Hy9nyL1UfJV7J9G9qlhqrqPhwbimEM6VPEQnZN3oKkiua-N5I32QxFQVlC6kQ-tqGq_5U3bQdm18zgCFW9dBNSbEKEzQLpgi6lArh6-U0hn7uJWVvR04OGyKXYyyg2QtStYmydpNxj6TOHc9iT87vUCtsqNW2X9pVcbekTJYWuUoce_GYgUcMPFl2WNlEMiWqsLBHU564ur00-atOtnROvQWIWPBOUamMmNvds30JWW8tbFbYx86z6RoV2Xs2aB9u1_iRIInlMiYnujl5J-nLe31InGHI8A2iOpe_I9JesnuVbSkKL9HHrKD1c91fIUQbVW_TqvxN2MfPd4 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFB60BfFFvButcgRBRUKzydzqi7TS0goti7XQt2EyM3ELa7I2uy_72_xxnjM7u20QfFsyE3bCuc65fIexd05Rv6ZXeagFz_mIZG6vcHhrtXuNEk4LR43Cp2fy-IJ_uxSXKeDWp7LKtU6Mitp3jmLku2hmi6pCb158mf3OaWoUZVfTCI27bLsccUrTbh8cno2_b_IISku-bpXRcrdHjR3zlniFFlJV-XJgjiJq_7-6-ZZxGhZO3rJERw_Zg-RCwv6K5o_YndA-ZvdOU5L8CfuDpIdVnQbcgHlD18DJpvsKxhQ-p8gg2NYDzfZEPxw-nIzPPwL6sZDwVnugQC30qF7mxB-w6AP4hNjZf4aITgsE9tAhR8U3LaD5892vq2XwkCrhp_gzzgeJpxifAxWDLHoI7SRWIEAfpk0-CdPZU3ZxdPjj63GehjTkTshqnjsr0MzKMFKVCrry2jYFt3ZU-WC5qBtVelGpWruqEc4LQqzyUhXCopbVjVPVM7bVdm14wcBKXtdeNtqHwLVX1usiKF9Li4-kVBn7tKaVma2wOEy8w2hpVpQ1SFkTKWuWGTsgcm52Eo52fNBd_zRJLM2ec4Ut8Y-LuuFNIfH2V4o6FAH9Wqe9y9h7YgZD0o4UdzY1LeCBCTfL7EuNDu1Ilni4ncFOlFI3XF6zk0laojc3PJ2xt5tlepMq39rQLXAP5TXp1isz9nzFfZtPqggMj0ueMTXgy8E3D1faq0nEEEdHW6N39_L_x3rF7pckLFTBI3bY1vx6EV6jEzav3yRJ-wtGrTZT priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ti9QwEA7nCeIX8d3qKSMIKlLttnlbQeQUjzthZeE8uG8hTVL3YG3P7S7o_jZ_nDNpd73iffDb0qTbtPNMZiYzecLYM6dov6ZXaSgFT_mIdG6cOYxa7bhSwmnhaKPw5Is8POGfT8XpDtscd9R_wPbS0I7OkzpZzF___PHrPSr8u6jwWr5pcR6O2UgMjIVURbq-wq7mvOCE-AnfZhXQ9nZZZsVFKtHWbTbRXPofA0MV-fz_nbUvmK1hSeUFG3Vwk93onUvY79Bwi-2E-ja7NunT53fYbwQFdBUc8JfmG5oKjrb7smBKC-u0Zgi29kCnfuLHgRdH0-OXgB4u9EysLdASLrQ48SwJObBqA_iey7N9C5G3FogGokGsxTstoGH0zfezdfDQ18jP8Wc8OSSOYnoMVCayaiHUs1ibAG2YV-kszM_vspODT18_Hqb98Q2pE7JYps4KNMAyjFShgi68tlXGrR0VPlguykrlXhSq1K6ohPOCuKy8VJmwOP_qyqniHtutmzo8YGAlL0svK-1D4Nor63UWlC-lxUtSqoS92sjKnHcsHSZGN1qaTrIGJWuiZM06YR9InNuexLAdLzSLb6ZXWDN2LrM5PjgrK15lEuPCXJQhC-jxOu1dwp4TGAwhEyXubL-dAQdMjFpmX2p0dUcyx8HtDXqi_rph8wZOZgN_g05lVhQYu4qEPd02051UE1eHZoV9KONJ8bBM2P0OfdtXKogmj0ueMDXA5eCdhy312Syyi6MLrtHve_gfz33EruekMVTgI_bY7nKxCo_RR1uWT6Li_QFcGDxE priority: 102 providerName: Scholars Portal |
| Title | The effect evaluation of Individual Placement and Support (IPS) for patients with substance use disorders: study protocol for a randomized controlled trial of IPS versus enhanced self-help |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34654464 https://www.proquest.com/docview/2730339565 https://www.proquest.com/docview/2582814416/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC8518218 https://doaj.org/article/9cc0a2a640bf4f0699625be0e193c8dc |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZtB6UvY_d664IGg20MN050zd7S0q4NpIRlhbwJWZKXQGKHOnnJb9uP25FsZzV724ttLAnLnLt0zieEPhrh6zWtiF3KaEx7XuYGiYGoVQ8ywYxkxhcKj-_4zT0dzdjsALGmFiYk7Zt0cZ4vV-f5Yh5yK9cr023yxLqT8SV4CRJMU_cQHQpCmhC9Ur9gYAltqmMk75agpMNWJUTNjAsS707QMfEoYpTTljEKmP3_auZHpqmdNvnIDl0_Q09rBxIPq4k-Rwcuf4GOx_UW-Uv0GwiPqywN_BfKGxcZvt3XXuGJXzz364JY5xb7kz3BC8efbyfTLxi8WFyjrZbYL9PiEpTLxnMH3pYO2xqvs_yGAzYt9lAPBfBTGKkxGD9brBY7Z3GdB7-Ex3A6SJjFZIp9Ksi2xC6fh_wDXLplFs_dcv0K3V9f_by8iesjGmLDONnERjMwstz1BBFOEit1llCte8Q6TVmaib5lRKTSkIwZyzxeleUiYRp0rMyMIK_RUV7k7hRhzWmaWp5J6xyVVmgrEydsyjW84lxE6GtDK7WukDhUiGAkVxWRFRBZBSKrXYQuPDn3PT2KdnhRPPxSNS-pgTGJ7sOHkzSjWcIh9uuz1CUOvFojrYnQJ88Myss6UNzoumQBJuxRs9SQS3Bne7wPkztr9QQZNe3mhp1UrSNKBY5jQgjEpyxCH_bNfqTPe8tdsYU-flfTx7w8Qm8q7tv_UsPEERItvmz9c7sFBCogiNcC9Pa_R75DJ30vUj61h52ho83D1r0H72yTdkAmZ6KDngyHo-kI7hdXd5MfnbDWAdfvsx5cx1R2gtT-AZiaRLY |
| link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827,74100,74657 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dixMxEA96gvoifrt6agRBRZbbNp_1RU7xaPV6FO4O-haySdYe1N162770b_OPcyZNe7cIvpVNlmaZ78nMbwh56xT2a3qVh1LwnPdQ5gaFg6jVDiolnBYOG4XHJ3J4zr9PxTQl3NpUVrnViVFR-8ZhjvwAzGzBGHjz4vPid45To_B2NY3QuEluccY48rma7gKuntKSbxtltDxoQV_HW0sIoIVULF93jFHE7P9XM18zTd2yyWt26Og-uZccSHq4ofgDciPUD8ntcboif0T-AOHppkqDXkF506aio13vFZ1g8hzzgtTWnuJkT_DC6fvR5PQDBS-WJrTVlmKalragXJbIHXTVBuoTXmf7iUZsWopQDw3wU3zTUjB-vvl1sQ6epjr4OfyM00HiKSanFEtBVi0N9SzWH9A2zKt8FuaLx-T86NvZ12GeRjTkTki2zJ0VYGRl6CmmgmZe26rg1vaYD5aLslJ9L5gqtWOVcF4gXpWXqhAWdKyunGJPyF7d1OEZoVbysvSy0j4Err2yXhdB-VJaeCSlysjHLa3MYoPEYWIEo6XZUNYAZU2krFln5AuSc7cTUbTjg-byp0lCaQbOFbYPf1yUFa8KCbFfX5ShCODVOu1dRt4hMxiUdaC4s6llAQ6MqFnmUGpwZ3uyD4fb7-wEGXXd5S07maQjWnPF0Rl5s1vGN7HurQ7NCvbgrSbGvDIjTzfct_skhlB4XPKMqA5fdr65u1JfzCKCOLjZGny75_8_1mtyZ3g2PjbHo5MfL8jdPgoO1vKIfbK3vFyFl-COLctXUeb-AtYUN9o |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgSBMviPsCAw4SEiAUNW3iS3lB41KtwKZKY1LfLMd26KSSlKV96W_jx3GO63aLkHirYkd1dO725-8w9spKuq_pZOpLXqRFn2xumFmsWs2wktwqbumi8MmpOD4vvk75NOKf2gir3PrE4KhdY2mPvIdhNstzzOZ5r4qwiMnn0YfF75Q6SNFJa2yncZPdwiiZURsHOd0VX32pRLG9NKNEr0XfHU4wsZjmQubpuhOYAn__v176WpjqQiivxaTRXXYnJpNwtJH-PXbD1_fZ_kk8Ln_A_qASwAaxAVe03tBUMN7dw4IJbaTTHiGY2gF1-cSMHN6MJ2dvATNaiMyrLdCWLbToaJakKbBqPbjI3dm-h8BTC0T70KBuhTcNYCB0za-LtXcQMfFz_Bk6hYRVTM6AYCGrFnw9C1gEaP28Smd-vnjIzkdffnw6TmO7htRykS9TazgGXOH7Mpde5U6ZKiuM6efOm4KXlRw4nstS2bzi1nHirnJCZtygv1WVlfkjtlc3tT9gYERRlk5UynlfKCeNU5mXrhQGHwkhE_ZuKyu92LBy6FDNKKE3ktUoWR0kq9cJ-0ji3M0kRu3woLn8qaOB6qG1mRngH2dlVVSZwDpwwEufecxwrXI2Ya9JGTTZPUrcmnh9ARdMDFr6SChMbftigIs77MxEe7Xd4a066egvWn2l3Ql7uRumNwkDV_tmhXPohJPqX5Gwxxvt231STrR4hSgSJjt62fnm7kh9MQts4phyK8zznvx_WS_YPpqb_j4-_faU3R6Q3RCshx-yveXlyj_DzGxZPg8m9xc10DwG |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effect+evaluation+of+Individual+Placement+and+Support+%28IPS%29+for+patients+with+substance+use+disorders%3A+study+protocol+for+a+randomized+controlled+trial+of+IPS+versus+enhanced+self-help&rft.jtitle=Trials&rft.au=Rognli%2C+Eline+Borger&rft.au=Aas%2C+Erlend+Marius&rft.au=Drake%2C+Robert+E&rft.au=Marsden%2C+John&rft.date=2021-10-15&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=22&rft.issue=1&rft.spage=705&rft_id=info:doi/10.1186%2Fs13063-021-05673-z&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |